Shackelford Pharma

Shackelford Pharma

About this raise

Shackelford Pharma is raising funds independently through Reg A+ crowdfunding with DealMaker Securities as the Broker-Dealer. It is a biopharmaceutical company dedicated to developing medicines for neurological diseases. The company is currently developing SP1707 as its first drug candidate as a long-acting cannabinoid formulation for patients suffering from seizures. Mark Godsy and Dr. Alan Shackelford founded Shackelford Pharma in 2018. The current crowdfunding campaign has a maximum target of $12.5 million. The campaign proceeds will be used for research and development and general working capital.

Expand

Investment Overview

Invested this round: $833,148

Deal Terms

Total Commitments ($USD)

Platform
DealMaker Securities
Start Date
12/12/2022
Close Date
Not Provided
Min. Goal
$1,500
Max Goal
$12,520,000
Min. Investment

$1,500

Security Type

Equity - Common

Series

Series A

SEC Filing Type

RegA+    Open SEC Filing

Price Per Share

$1.50

Pre-Money Valuation

$68,195,651

Company & Team

Company

Year Founded
2018
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Distribution Model
B2B/B2C
Margin
Medium
Capital Intensity
High
Location
Vancouver, British Columbia
Business Type
Growth
Company Website
Visit Website

Team

Employees
7
Prior Founder Exits?
Yes
Founder Name
Mark Godsy
Title
CEO
Founder Name
Alan Shackelford
Title
CMO and Director
Founder Name
Avi Livnat
Title
VP Clinical and Regulatory Affairs and Director

Financials

 Revenue
$0
 Monthly Burn
$293,345
 Runway
20.9 months

Balance Sheet

Cash and Cash Equivalents

$6,143,513

Accounts and Notes Receivable

$54,611

Total Assets

$6,411,228

Accounts Payable & Accrued Liabilities

$403,212

Long Term Debt

$0

Total Liabilities

$6,411,228

Total Stockholders' Equity

$6,008,016

Total Liabilities and Equity

$6,411,228

Statement of Comprehensive Income Information

Depreciation and Amortization

$6,552

Net Income

$-3,520,134

Earnings Per Share - Basic

$-0.09

Earnings Per Share - Diluted

$-0.09

Auditor: Dale Matheson Carr-Hilton Labonte LLP
Create a free account today to gain access to Kingscrowd analytics and financials.

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings Kingscrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Company Funding & Growth

Funding history

Total Prior Capital Raised
$9,300,000
VC Backed?
No
Close Date Platform Valuation Total Raised Security Type Status Reg Type
12/14/2023 DealMaker Securities $68,195,651 $833,148 Equity - Common Funded RegA+
08/20/2021 Dalmore Group $37,595,931 $9,303,845 Equity - Common Funded RegA+
Create a free account today to gain access to Kingscrowd analytics.

Growth Charts

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Founders: enhance your startup's credibility on Kingscrowd. Create an account to claim this raise page.
Add to portfolio
Shackelford Pharma on DealMaker Securities 2022
Platform: DealMaker Securities
Security Type: Equity - Common
Valuation: $68,195,651
Price per Share: $1.50

Follow company

Follow Shackelford Pharma on DealMaker Securities 2022

Buy Shackelford Pharma's Deal Report

Warning: according to the close date for this deal, Shackelford Pharma may no longer be accepting investments.

Shackelford Pharma Deal Report

Get Kingscrowd's comprehensive report on Shackelford Pharma including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Shackelford Pharma is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Shackelford Pharma deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge